Diagnostic accuracy and safety of endoscopic ultrasound-guided fine needle biopsy for evaluating mediastinal pathologies

Table 3 Diagnosis, management plan, and survival status of patients, n (%)

Variables	Total (n = 77)1
EUS-FNB specimen
Mediastinal lesion/with esophageal/gastric lesion	16 (20.8)
Mediastinal LN/with esophageal/pancreatic/spleenic mass	42 (54.5)
Para-aortic mass/with gastric/duodenal lesion	7 (9.1)
Porta hepatis LN/with gastric/duodenal/Liver/pancreatic lesion	12 (15.6)
EUS-FNB tissue nature
Benign	45 (58.4)
Malignant	32 (41.6)
Definitive tissue diagnosis
Malignant
Lymphoma	9 (11.7)
Adenocarcinoma	8 (10.4)
Squamous cell carcinoma	8 (10.4)
Metastatic carcinoma	4 (5.2)
NETs/non-small cell carcinoma	5 (6.5)
Benign
Anthracotic/silicotic nodule	4 (5.2)
Esophageal candidiasis/gastritis	2 (2.6)
Sarcoidosis	8 (10.4)
TB	11 (14.3)
Reactive lymphoid tissue	16 (20.8)
Thymoma/solitary fibrous tumor	2 (2.6)
Treatment
Anti-TB drugs	10 (13.0)
Chemotherapy	14 (18.2)
Conservative therapy	22 (28.6)
Steroids/immunosuppressive therapy	3 (3.9)
Palliative care	5 (6.5)
PEG tube placement	3 (3.9)
Radiation therapy	3 (3.9)
Surgical resection	3 (3.9)
No treatment	14 (18.2)
Patient’s outcome
Survived	53 (68.8)
Deceased	10 (13.0)
Loss to follow-up/LAMA	14 (18.2)

¹Percentages are presented in columns.

EUS-FNB: Endoscopic ultrasound-guided fine-needle biopsy; LN: Lymph node; NET: Neuroendocrine tumor; TB: Tuberculosis; LAMA: Leave against medical advice.